Author

Indu Shrivastava

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

OpenAlex ID: A5117729445

Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens

2026 · Jennifer Prescott, Christina M. Parrinello, et al. · Blood Neoplasia · 1

A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens.

2025 · Jennifer Prescott, Christina Parrinello, et al. · Journal of Clinical Oncology

Works count: 2

Citation count: 1

H-index: 1

I10-index: